Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports

Malak Almutairi,Aljoharah Algabbani,Ajbaa Alasiri,Ali Alhomaidan,Amani S. Alqahtani
DOI: https://doi.org/10.1007/s43441-024-00635-4
2024-03-29
Therapeutic Innovation & Regulatory Science
Abstract:This study aims to explore the characteristics of drug recall announcements issued over six years by the SFDA in Saudi Arabia. Additionally, to examine the patterns of voluntary drug recall requests by pharmaceutical companies (both innovator and generic) in response to product defects.
pharmacology & pharmacy,medical informatics
What problem does this paper attempt to address?